Malaria Research and Treatment / 2017 / Article / Tab 1

Research Article

Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites

Table 1

Long-term efficacy of depot IM-decoquinate (DQ) formulation (nano- and microsuspension) dosed with single intramuscular injection at 80, 120, or 240 mg/kg before treatment given 2, 4, 6, or 8 weeks early and monitoring by using in vivo imaging system (IVIS) in C3H mice ().

Test agentsDose (mg/kg) RegimenLiver suppression rate (%)Blood infection by FCM Number of C3H miceEffects
24 h48 h72 hChallengedProtected completelyCausal prophylaxis

IM nano-DQ
(0.43 µm)
120−8 weeks71.870.565.75/5500/5Mild suppression
120−6 weeks79.090.892.54/5511/5Partial causal prophylaxis
120−4 weeks89.497.699.61/5544/5Partial causal prophylaxis
120−2 weeks97.91001000/5555/5Full causal prophylaxis
80−2 weeks10091.71001/5544/5Partial causal prophylaxis

IM nano-DQ(0.43 µm)240−8 weeks1001001000/5555/5Full causal prophylaxis
240−6 weeks10098.91000/5555/5Full causal prophylaxis

IM micro-DQ
(8.31 µm)
120−8 weeks1001001000/5555/5Full causal prophylaxis
120−6 weeks10098.81000/5555/5Full causal prophylaxis
120−4 weeks10099.31000/5555/5Full causal prophylaxis
120−2 weeks10099.61000/5555/5Full causal prophylaxis

IVIS study: decoquinate (DQ) injected 2, 4, 6, and 8 weeks early to the challenge with 10,000 sporozoites (SPZ) intravenously in C3H female mice, which will be monitored with IVIS on days 1, 2, and 3 after SPZ inoculation. The blood parasitemia will be measured by flow cytometry up to 30 days after inoculation.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.